Study of ENERGI-F705 for Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests an experimental medicine called ENERGI-F705 to see if it can help people with Parkinson's disease. It focuses on people who have had the disease for at least 2 years and are currently on standard Parkinson's medications, without major movement complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 75 years old.
- You have been diagnosed with Parkinson's disease for at least 2 years.
- You are not having significant movement fluctuations (on-off periods) or involuntary movements (dyskinesias).
- You are currently taking a stable dose of Parkinson's medication (e.g., levodopa) for the last 3 months.
- You have not had brain surgery for Parkinson's, a recent cancer diagnosis, or a history of gout or kidney stones.
- You are willing to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental oral medication (TJ0113) can improve symptoms in people diagnosed with Parkinson's disease before age 50. Participants must already be taking levodopa and keep their current Parkinson's medications unchanged during the study.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This study tests whether an experimental medicine called SUL-238 can improve energy levels in the brain cells of people with early, untreated Parkinson's. It uses a special type of MRI to see if the medicine affects brain energy.
This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.